Utilization of the TAD Device for Dispensing Pain Medications in Hospice Patients

Intent Solutions

Status: Completed

Conditions: Satisfaction, Personal; Medication Adherence

Treatments: Device: TAD

Study type: Interventional

Funder types: Industry

Identifiers

NCT03940534

6195-001

Details and patient eligibility

About

A novel device, TAD, has been developed to aid adherence to prescribed regimens and may have a roll in hospice pain management. This study aims to assess medication adherence relating to missed doses or improperly timed doses with and without the aid of a mobile device as a primary endpoint. Secondary endpoints will be patient, nursing, and provider satisfaction.

Full description

This study is a randomized crossover study in which patients will be randomized to start with or without a mobile device assisting the patient or caregiver in using the device. The investigators aim to enroll 20 patients across 3 sites. Each patient is expected to participate in the study for 12 weeks. After the first 2 weeks of participation, the patient will either begin using the mobile device to assist or will stop using the mobile device for the next 2 weeks. after the initial 4 weeks, the patient will choose to continue with or without using the mobile device.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• any patient taking morphine ER or Oxycontin on one of three hospice home teams

Exclusion criteria

• pregnancy
• inability to demonstrate competent use of the device
• age less than 18

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

Start with Mobile Device

Active Comparator group

Treatment:

Device: TAD

Start without Mobile Device

Active Comparator group

Treatment:

Device: TAD